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a b s t r a c t
Hepatitis C virus (HCV) is a major global health burden with 2–3% of the world's population being
chronically infected. Persistent infection can lead to cirrhosis and hepatocellular carcinoma. Recently
available treatment options show enhanced efﬁcacy of virus clearance, but are associated with resistance
and signiﬁcant side effects. This warrants further research into the basic understanding of viral proteins
and their pathophysiology. The p7 protein of HCV is an integral membrane protein that forms an ion-
channel. The role of p7 in the HCV life cycle is presently uncertain, but most of the research performed to
date highlights its role in the virus assembly process. The aim of this review is to provide an overview of
the literature investigating p7, its structural and functional details, and to summarize the developments
to date regarding potential anti-p7 compounds. A better understanding of this protein may lead to
development of a new and effective therapy.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
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Introduction
Hepatitis C virus (HCV) infection is a global health problem
with an estimated 130–170 million people infected worldwide
(Levrero, 2006). In chronically infected individuals development
of cirrhosis and hepatocellular carcinoma are common clinical
outcomes (Thomas, 2013). A combination of pegylated interferon
alpha (peg-IFN-α) and ribavirin is the current standard of care, but
is associated with poor tolerance and variable efﬁcacies. Recently,
an increase in the sustained virological response to HCV treatment
was achieved through the use of direct-acting antiviral compounds
in combination with peg-IFN-α and ribavirin. Unfortunately,
these protease inhibitors are susceptible to the development of
resistance and are associated with adverse side effects in addition
to those already observed with the canonical treatment. Fortu-
nately, additional promising antiviral compounds are in line for
further analysis and development, and some, including novel
classes of inhibitors, will be available in the clinic in the very near
future (Feld and Hoofnagle, 2005). We believe that a greater
understanding of the intricacies of protein function in the viral
life cycle will provide insightful information plausibly leading to a
broader range of better treatment options.
HCV belongs to the Hepacivirus genus within the Flaviviridae
family. It has a single-stranded RNA genome of positive polarity.
Classiﬁcation of HCV has expanded to include seven discernibly
different genotypes and multiple subtypes (Kuiken and Simmonds,
2009). HCV mainly infects hepatocytes through a sequential binding
to multiple host receptors (CD81, scavenger receptor class B type 1
(SR-B1), Low density lipoprotein (LDL), claudin-1 and occludin), which
synergistically promote tight binding and internalization of the virion.
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Next, a poorly understood pH-dependent fusion and uncoating step
takes place, releasing the viral genome into the cytoplasm (HCV entry
reviewed in (Zeisel et al., 2013)). The viral RNA genome is then
recognized by host ribosomes via the internal ribosomal entry site
(IRES) sequence located at the 50 end of the untranslated region (UTR)
in order to mediate viral genome translation. The translated poly-
peptide chain is approximately 3000 amino acids (aa) long and is
co- and post-translationally processed by host- and virus-encoded
proteases in association with the endoplasmic reticulum (ER) to
generate the individual mature forms of the viral proteins (Fig. 1)
(Hoffman and Liu, 2011). The envelope glycoproteins E1 and E2, as
well as the core protein comprise the physical structure of the virion.
The non-structural (NS) proteins (NS3, NS4A, NS4B, NS5A and NS5B)
form a complex that performs viral RNA ampliﬁcation (HCV RNA
replication reviewed in (Moradpour et al., 2007)). Many of these
proteins also interact in some way to support viral assembly (Appel et
al., 2008; Ma et al., 2008; Masaki et al., 2008; Jones et al., 2009;
Kohlway et al., 2013; Han et al., 2013; Hughes et al., 2009, 2009). The
viral proteins p7 and NS2 are not involved in viral RNA replication
(Jones et al., 2007; Steinmann et al., 2007,; Jirasko et al., 2008, 2010;
Popescu et al., 2011; Stapleford and Lindenbach, 2011). NS2 is a
transmembrane autoprotease that is composed of two domains: a N-
terminal membrane anchor and a C-terminal cysteine protease, which
mediates cleavage from the adjacent NS3 protein after translation
(Hijikata et al., 1993; Lorenz et al., 2006). NS2 is required for HCV
infectivity in vivo and virus production in HCV cell culture system
(Pietschmann et al., 2006; Kolykhalov et al., 2000). It has been shown
that NS2 homodimerizes and can interact with other viral proteins
including p7. These interactions have led to the suggestion that NS2
has a major role in the HCV assembly process (Jirasko et al., 2008,
2010; Stapleford and Lindenbach, 2011; Dimitrova et al., 2003;
Yi et al., 2009).
In the past, HCV research has been hindered by the inability to
study the virus in the context of a complete life cycle. The replicon
system was a systematic breakthrough that harnessed a neomycin
selection gene and an ECMV IRES to mediate the translation of
HCV NS proteins and enable RNA replication in vitro (Lohmann et
al., 1999). Considering the replicon system failed to yield infectious
Fig. 1. HCV genome translation and processing. The HCV genome (top panel) contains an approximately 9.6 kb open reading frame (ORF) ﬂanked by 50 and 30 un-translated
regions (UTR). Translation is initiated at the IRES (internal ribosome entry site) sequence within the 50 UTR to generate a 3000aa polypeptide chain comprised of unprocessed
structural proteins core and envelope glycoproteins 1 and 2 (blue boxes; middle panel), as well as the non-structural proteins 2-5B (red boxes). The viral protein p7 is neither
a structural or non-structural protein (green box). The polypeptide undergoes co- and post-translational processing in the ER to generate the mature form of the viral
proteins (enzymatic digestion sites are indicated by symbols (bottom panel) and are deﬁned in the inset).
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virus and had no structural protein expression, the development
of the pseudoparticle system (HCVpp) partially ﬁlled this gap.
The HCVpp system exploited retrovirus biology to create chimeric
viruses containing HCV glycoproteins on the surface. In this
system 293 T cells were used for generation of particles containing
E1 and E2, these particles could then be used to infect permissive
hepatocyte cell lines and entry could be analyzed through the use
of a reporter gene (luciferase or GFP) in the recombinant construct
(Bartosch et al., 2003; Hsu et al., 2003). The discovery of the
hepatitis C virus cell culture system (HCVcc) has provided the
investigative capacity to study the whole HCV life cycle, including
assembly and release, and thereby opened the door for mutagen-
esis studies of viral proteins in order to identify their individual
functions and interactions within the HCV life cycle (Lindenbach et
al., 2005; Wakita et al., 2005; Zhong et al., 2005). The HCVcc
system revolves around the replicative power of the JFH-1 (Geno-
type 2a) or the H77 (Genotype 1a) construct (Wakita et al., 2005;
Yi et al., 2006). The system provides insightful capabilities through
the implementation of adaptive mutations and chimeric con-
structs that increase viral titers facilitating the assessment of
genotypic variability (Pietschmann et al., 2006; Lindenbach et al.,
2005; Russell et al., 2008).
The virus assembly process is initiated by recruitment of core
to the surface of lipid droplets (LD) (an ER-associated organelle
primarily functioning to store neutral lipids and cholesterol
esters), which are believed to provide a platform for nucleocapsid
formation (Boulant et al., 2006; McLauchlan et al., 2002). Viral
RNA packaging and downstream envelopment steps are still
poorly understood, but NS2 and p7 are believed to support the
communication between replication complex and maturing vir-
ions (Jirasko et al., 2010; Stapleford and Lindenbach, 2011; Phan et
al., 2009; Boson et al., 2011). The assembly process is hypothesized
to coincide with the host VLDL pathway, and newly-formed virions
are released as lipo-viral particles (LVPs) (HCV assembly reviewed
in (Bartenschlager et al., 2011)).
The HCV p7 protein is located between E2 and NS2 and in its
mature form is 63aa in length (Lin et al., 1994). In artiﬁcial lipid
membranes p7 performs ion-channel activity, and is therefore
included in the group of viral proteins termed viroporins (Grifﬁn
et al., 2003). These proteins are known to modulate membrane
permeability to support virus entry, assembly or release (viropor-
ins reviewed in (Nieva et al., 2012)). Depending on the genotype,
p7 activity can be hindered by multiple ion-channel blockers, such
as amantadine, rimantadine and iminosugar derivatives (Grifﬁn et
al., 2003, 2008; Pavlovic et al., 2003; Steinmann et al., 2007; Foster
et al., 2011). In addition, p7 is dispensable for viral RNA replication,
but is important for in vivo infectivity in the chimpanzee model,
and for production of infectious HCVcc (Jones et al., 2007;
Steinmann et al., 2007; Sakai et al., 2003; Brohm et al., 2009;
Atoom et al., 2013). The function of p7 in the HCV life cycle
remains a matter of debate, but multiple studies have placed its
role to be at a late stage of the virus assembly process (Atoom et
al., 2013; Gentzsch et al., 2013). In this review we aim to
summarize the functional and structural comprehension achieved
to date in the p7 ﬁeld. We ﬁrmly believe that p7 represents an
attractive target for novel HCV treatment, and a better under-
standing of its function is of the utmost importance for develop-
ment of a comprehensive therapeutic regimen.
HCV p7 processing, topology, and localization
The p7 protein was identiﬁed through expression of a series of
C-terminally truncated HCV polyproteins fused to a human c-myc
epitope tag. This analysis located p7 between the envelope
glycoprotein E2 and the NS2 protein (Fig. 1) (Lin et al., 1994).
Homologous proteins have been identiﬁed in the Pestivirus genus,
e.g., bovine viral diarrhea virus (BVDV), classical swine fever virus,
and border disease virus, all containing such a characteristic
protein between E2 and NS2 (Elbers et al., 1996). However,
Flaviviruses yellow fever virus, dengue virus, and West Nile virus
do not encode a protein homologous to p7 (Murray et al., 2008).
Upon HCV genome translation, p7 processing is mediated by
host-encoded proteases (Fig. 1) (McLauchlan et al., 2002; Reed and
Rice, 2000), but scission at the E2-p7 and p7-NS2 junctions is
delayed, resulting in the presence of precursor E2-p7-NS2 poly-
proteins. The cleavage at the E2-p7 junction is incomplete and
performed by a unique mammalian signal peptidase leading to the
presence of E2 and p7 mature forms, as well as some E2-p7 species
(Lin et al., 1994; Dubuisson et al., 1994; Mizushima et al., 1994).
Partial cleavage was attributed to a structural determinant located
N-terminal to the signal peptides. This is supported by the ﬁnding
that fusion of reporter proteins N-terminal to the signal peptides
improves cleavage efﬁciency (Carrere-Kremer et al., 2004). The
function of E2-p7 or p7-NS2 precursors is yet unidentiﬁed, but
hypotheses have been developed: (i) the precursor itself plays a
role in the HCV life cycle, (ii) the precursor could be important for
regulating the kinetics and/or levels of ﬁnal product expression to
prevent premature virus assembly (Carrere-Kremer et al., 2004;
Shanmugam and Yi, 2013) (such a case was illustrated in the
coordinated cleavage of C-preM in the Murray Valley encephalitis
virus (Stocks and Lobigs, 1998)), and (iii) the E2-p7 precursor
might be important for pulling p7 into the physical composition of
the virion by retaining a pool in the ER as E2-p7 form (Grifﬁn et al.,
2005). However, it's likely that cleavage of E2-p7 precursors play a
regulatory role because complete separation of E2 and p7 by
insertion of an EMCV IRES between these two proteins moderately
reduced the level of virus production in the HCVcc system. This
suggests the E2-p7 precursor serves no functional purpose on its
own, but that a temporal dependence on E2-p7 processing is
critical for virus production (Jones et al., 2007; Shanmugam and Yi,
2013). In trans-complementation studies, it was found that
whether p7 alone or p7 in the context of cleavage intermediates
were sufﬁcient for restoration of virus production depended on
the extent of the original p7 deletion and the degree of indirect
effects such deletions had on polyprotein processing. Brohm et al.
(2009). In summary, it is clear that the p7-including processing
intermediates in some way impact virus production, but whether
these intermediates have speciﬁc functions within the viral life
cycle requires further investigation.
The p7 protein is a polytopic membrane protein that crosses
the endoplasmic membrane twice, forming trans-membrane
domain 1 (TM1) and trans-membrane domain 2 (TM2) connected
by a short segment (Fig. 2A and B), with its N- and C- termini
oriented toward the cytosol (Lin et al., 1994). The subcellular
localization of p7 was identiﬁed by fusion of p7 to CD4 or Myc.
This fusion in HepG2 cells identiﬁed a large fraction of p7 in an
early compartment of the secretory pathway suggesting the
presence of a retention signal maintaining localization of p7 in
the ER (Carrere-Kremer et al., 2002). Conversely, intracellular
staining of GFP- or Flag-tagged p7 in 293 T cells showed that p7
partially co-localized with mitochondria and adjacent membrane
structures (Grifﬁn et al., 2004). Interestingly, staining of native and
tagged p7 demonstrated that untagged p7 was exclusively
detected on the ER, while N-terminally tagged p7 was detected
on ER or mitochondrial adjacent membranes. This work is indica-
tive of complex trafﬁcking of p7 that could be regulated by the
cleavage from its upstream signal peptide and targeting signals
present within the protein sequence (Grifﬁn et al., 2005). Immu-
noﬂuorescence (IF) and electron microscopy (EM) in the context of
a full-length, RNA replication-competent HCV genome derived
A.M. Atoom et al. / Virology 462-463 (2014) 377–387 379
from the JFH-1 sequence, showed that eGFP-p7 or p7 tagged with
HA 4aa downstream of the potential E2-p7 cleavage site were
localized only at the ER in Huh7 cells. However, it is important to
note that these tags likely disrupted virus production (Haqshenas
et al., 2007). Consequently, recent studies have double-HA-tagged
p7 at the N-terminus in Jc1 (a genotype 2a chimeric construct
containing J6 and JFH-1 genes with a junction point within NS2)
creating a viable virus. This replicating virus showed signiﬁcant
co-localization of p7 with ER markers and a lesser extent of
association with mitochondrial or lipid droplet markers. p7
showed a reticular staining pattern that mainly co-localized with
HCV E2 and partially with NS2, NS3, and NS5A (Vieyres et al.,
2013). Hypothetically, p7 localization with multiple organelles
may be indicative of this protein's dual role in HCV assembly
and trafﬁcking of nascent virions through multiple cellular
pathways.
The relatively small size of p7 and its membrane integration
topology have made analysis of localization and function laborious
and sometimes inconclusive. It is possible that the accessibility
of antibodies or the duration of infection chosen in the above-
mentioned literature inaccurately identiﬁed localization of p7 in
multiple cellular compartments. Therefore, more sensitive proteo-
mic analysis for p7 tracking and localization on multiple separated
cellular organelles at various times during HCV infection in cell
culture is needed in order to gain more reliable insights into the
role(s) of p7 in the HCV life cycle.
Ion-channel function and potential anti-p7 compounds
The p7 proteins of BVDV and HCV were originally proposed to
oligomerize and form ion-channels by Harada et al. (2000) and
Carrere-Kremer et al. (2002), respectively. Oligimerization was
observed when it was shown that p7 formed a hexamer in artiﬁcial
membranes and functioned as a calcium ion-channel in black lipid
membranes. The ion-channel activity of p7 in this assay could be
abrogated by the drug Amantadine (Grifﬁn et al., 2003). The ion-
channel activity of a cross-linked p7 lead to inclusion of this protein
in the viroporin family, which consists of small hydrophobic
proteins with the ability to permeabilize membranes for ion and
small molecule movement (examples are listed in Table 1 and
reviewed in (Nieva et al., 2012; Gonzalez and Carrasco, 2003; Wang
et al., 2011; Liang and Li, 2010; Ruch and Machamer, 2012)). An
important example is the viral protein M2 of inﬂuenza virus, which
forms proton ion-channels and is activated in acidic environments.
M2 triggers viral uncoating during entry within acidic endosomes
and protects the HA glycoprotein from premature maturation in the
trans-golgi network during egress, indicating that a multitude of
functions can be performed by virally encoded ion-channels. The
channel activity of M2 is blocked by amantadine and rimantadine,
suggesting the two could be used to treat inﬂuenza infection
(reviewed in (Kelly et al., 2003; Schnell and Chou, 2008)).
p7 conductance across artiﬁcial lipid membranes was conﬁrmed
when pentamer formation was shown to be necessary for accom-
modation of ion transport. This study also reported a concentration-
dependent inhibition of p7 channel activity after treatment with
long-alkyl-chain iminosugar derivatives such as N-nonyl deoxyga-
lactonojirimycin (NN-DGJ), N-nonyl deoxynojirimycin (NN-DNJ)
and N-7-oxanonyl-6-deoxy-DGJ (Pavlovic et al., 2003). These com-
pounds were tested because of their potent anti-viral activity
against BVDV (Durantel et al., 2001).
In cell-based assays, Grifﬁn et al. demonstrated that expression
of p7 in mammalian cells can substitute for inﬂuenza virus M2
channel activity to maintain infectivity of inﬂuenza, and that this
activity also could be blocked by the antiviral drug amantadine. In
addition, it also was shown that mutation of the two basic residues
within the p7 cytoplasmic loop abrogated ion-channel activity,
highlighting the importance of this loop for p7 function (Grifﬁn et
al., 2004). A subsequent study conﬁrmed the ion-channel function
of p7 in planar lipid bilayer membranes and showed that p7
channels were permeable to potassium and sodium ions, with
limited permeability to calcium ions (Premkumar et al., 2004).
Later, ﬂuorescence-based liposome assays were developed to more
conveniently assay for p7 channel activity and therapeutic targets
within p7. Employment of such assays using p7 from genotype 1b
showed a dose-dependent release of ﬂuorescent indicator when
mixed with liposomes. The release activity was blocked by the
drugs amantadine, rimantadine and several related compounds
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Fig. 2. p7 topology and sequence analysis. (A) Representative diagram of p7 topology within the endoplasmic reticulum (ER) showing the two transmembrane domains
(TM1) and (TM2) connected by a cytoplasmic loop. Both N- and C-termini are oriented toward the ER lumen. (B) Examples of commonly used isolates with genotype/subtype
sequence variability and domain locations shown. TM1 (aa13-32) and TM2 (aa38-57) are indicated by dark gray boxes. The two conserved basic residues in the cytoplasmic
loop are shown in red.
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(StGelais et al., 2007). Taken together, these similarities with M2
protein function and inhibition provide strong evidence that p7 is
also a viroporin.
Investigation of sequence determinants in p7 critical for ion-
channel activity or drug sensitivity led to a number of insightful
outcomes concerning the role of the putative channels. One report
showed that the leucine-rich motif at the C-terminal end of TM2
partially contributed to drug sensitivity. Mutation of the two basic
residues within the cytoplasmic loop (K33/R35 in G1b) was found
to affect channel activity and caused disruption of the ion-channel
insertion into membranes. The histidine at residue 17 in TM1 also
showed signiﬁcant effects on ion-channel function (StGelais et al.,
2009). H17 is part of a HXXX(Y/W)-like motif that is also found in
inﬂuenza M2 and is integral for ion-channel opening (Meshkat et
al., 2009). H17 was shown to be in a critical position in the ion
pore, demonstrating its key role in ion-channel conductance
(Chew et al., 2009). Additionally, the L20F mutation and F25A
polymorphism in HCV p7 were found to confer adamantane and
iminosugar resistance, respectively (Foster et al., 2011). These
ﬁndings highlight the importance of mutational analyses of the
p7 sequence and the associated ion-channel activity, with major
implications on drug binding and potential identiﬁcation of novel
inhibitors.
p7 channel activity had never been tested in a cell culture-
based assay recapitulating the entire HCV life cycle because such a
system (HCVcc) was not established until 2005 (Lindenbach et al.,
2005; Wakita et al., 2005; Zhong et al., 2005). In contrast with
earlier studies, discrepancy was observed when the HCVcc system
was employed to characterize the potential antiviral effects of
amantadine and iminosugar derivatives (NN-DGJ, NN-DNJ and NB-
DNJ). It was found that amantadine did not affect virus release,
infectivity or ion-channel activity of JFH-1 (G2a) or chimeric
genomes (H77 (G1a), Con1 (G1b), and J6 (G2a)). Contrarily, the
iminosugar derivatives reduced virus titers in a dose-dependent
manner in the context of multiple genotypes, primarily at virus
assembly or release steps (Steinmann et al., 2007). The iminosugar
derivatives NN-DGJ, NN-DNJ and NB-DNJ have been shown also to
target cellular α-glucosidase I and II, and their inhibition leads
to misfolding of various host (Bergeron et al., 1994) and viral
glycoproteins such as BVDV E2 (Branza-Nichita et al., 2001) and
gp120 of HIV (Fischer et al., 1995). With this in mind, the above-
mentioned effect of iminosugar derivatives on virus production
could be attributed to alteration in HCV envelope proteins, as
shown previously (Steinmann et al., 2007) or to a manipulation of
a host cellular glycoprotein crucial for virus propagation in cell
culture. Similar discrepancy was also observed in a related protein
called p13-c of GBV-B, whereby amantadine inhibited the function
of p13-c ion-channel activity but failed to inhibit replication and
secretion of GBV-B from virally-infected marmoset hepatocytes
(Premkumar et al., 2006).
The development of the HCVcc system introduced greater
opportunities for p7 characterization. Grifﬁn et al. extensively
differentiated the genotype- and subtype-dependent sensitivity
of p7 to multiple inhibitors using both HCVcc and artiﬁcial
membrane assays. It was found that p7 from the JFH-1 isolate
was not blocked by amantadine in HCVcc or liposome-based
assays, whereas amantadine successfully inhibited G3a in both
systems. Amantadine inhibits J4 (G1b) while rimantadine was able
to inhibit both JFH-1 and J4 channel activity and virus production.
In addition, the iminosugar derivatives NN-DGJ and NN-DNJ
reduced infectious virus production for genotype 2a and 1b in a
dose-dependent manner, with no observed effect on viral protein
synthesis, processing, HCV RNA replication or cellular cytotoxicity
(Grifﬁn et al., 2008). Until now, differing results have been
obtained with various inhibitors in the context of different
genotypes. These contrasting results suggest that p7 inhibitors
may need to be developed in a genotype-speciﬁc manner.
Interestingly, p7 ion-channel activity was identiﬁed in native
cell membrane vesicles and infected cells by measuring Hþ proton
conductance and ﬂuorescent detection of lysosomal pH indicators.
Similarly, expression of p7 in HEK-293FT cells equilibrated Hþ
conductance. HCV infection increased lysosomal pH in infected
cells, but defective ion-channel mutants yielded no such increase.
Furthermore, amantadine, rimantadine and hexamethylene
amiloride block Hþ conductance through native vesicular mem-
branes (Wozniak et al., 2010). In a very recent article, Atkins et al.
Table 1
Examples of known viroporins. Ion-channel names and their respective virus and family names are shown (1st and 2nd columns). The known or expected functions are listed
(3rd column). The number of monomers needed to form the channel upon oligomerization and the classiﬁcation are shown (4th column). Potential inhibitors (5th column).
Abbreviations: HA: Hemagglutinin, HIV-1: Human immunodeﬁciency virus type 1, Vpu: viral protein U, CoV: Coronavirus. (Table information is gathered from references
(Nieva et al., 2012; Gonzalez and Carrasco, 2003; Wang et al., 2011; Liang and Li, 2010; Ruch and Machamer, 2012)).
Viroporin
name
Virus/family Main function Oligomerized state/Class* Inhibitors
Inﬂuenza A M2 Orthomyxoviridae 1. Viral genome uncoating.
2. Assembly of functional HA conformation
Tetramer/Class IA Amantadine and Rimantadine
HIV-1 Vpu Retroviridae 1. Facilitate budding of newly formed virion.
2. Enhance degradation of CD4.
Pentamer/Class IA Hexamethylene amiloride, BIT225
Picornavirus
P2B
Picornaviridae 1. Modulate virus release and host cell apoptosis
(suggested)
Dimer or tetramer/Class IIB DIDS (classic anion exchanger
inhibitor)
tested only in Enterovirus
CoV-E Coronaviridae 1. Induce assembly by enhancing membrane
scission.
2. Induce virion release.
Dimer, tetramer, or pentamer/
Class1A
Hexamethylene amiloride
Class I – single TM domain.
Subtype A: N-terminus oriented toward membrane lumen.
Subtype B: N-terminus oriented toward cytosolic face.
Class II – forms helix-turn-helix hairpin motifs.
Subtype A: both termini oriented toward membrane lumen.
Subtype B: both termini oriented toward the cytosolic space.
n Classiﬁcation.
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provided new evidence suggesting that p7 directly inﬂuences pH
maturation via an as yet undeﬁned mechanism (Atkins et al.,
2014). This strongly advocates the importance of ion-channel
activity during virus propagation.
A small compound termed BIT225 was shown to inhibit HIV
production at a late stage in the viral life cycle by blocking Vpu
ion-channel activity and impeding virus release from monocyte-
derived macrophages (Khoury et al., 2010). BIT225 was also shown
to bind p7 using a computational model of a p7 monomer, along
with amantadine, rimantadine and NN-DNJ (Wang et al., 2013).
BIT225 was shown to inhibit p7 ion-channel activity in lipid
membranes and demonstrated antiviral activity in a BVDV infec-
tion assay (Luscombe et al., 2010).
A small number of clinical trials that included potential p7
inhibitors have been performed to date. Combination therapy of
amantadine and IFN-α exhibited an insigniﬁcant correlation
between amino acid variation within p7 and response to treat-
ment in G1a/b-infected individuals. However, a L20F mutation was
observed more often in non-responder patients infected with G1b
receiving this combination therapy, which gives weight to the
theory that amantadine targets p7 (Mihm et al., 2006). Subse-
quently, an increase in early virological response was observed in
G1a/b patients treated with IFN-α, ribavirin and amantadine, yet
sustained virological response rates remained the same as the arm
receiving standard of care (Castelain et al., 2007). Such early
inhibition was observed previously when a combination of aman-
tadine, ribavirin and IFN-α was shown to reduce plasma viral RNA
levels in patients in a phase 1 trial (Lake-Bakaar et al., 2003). These
data indicate that amantadine could be useful in the case of new
infections or to promote viral decay before the establishment of
persistent infection.
It is still premature to include an ion-channel inhibitor with
IFN-α and ribavirin. The discrepancies observed among the inhibi-
tion studies performed to date could be attributed to system
inconsistencies, e.g., artiﬁcial membrane, liposome assay or HCVcc,
and/or use of dissimilar p7 genotypes studied in native form
versus tagged versions of the protein. Clinical trial data is still
conﬁned to response rates and lacks drug delivery analysis,
plausibly accountable for minimal therapeutic outcomes. Comple-
tion of extensive mutational analyses on p7 could further our
structural and functional understanding of the ion-channel and
identify speciﬁc regions within p7 that could represent novel
therapeutic targets. Subsequent or concomitant analyses of patient
genomes from clinical trials could provide penetrative information
concerning resistance and susceptibility in the p7 region.
NMR analyses of p7
NMR structural analysis was performed on p7 from G1b and
showed that the N-terminal portion formed an α-helix (aa1-14)
and TM1 (aa15-18) and TM2 (aa19-32) formed α-helixes con-
nected by a short loop (aa33-39) (Montserret et al., 2010). How-
ever, the structural features and the helix lengths observed
through NMR were contrastive to the molecular model of p7
(Carrere-Kremer et al., 2002; StGelais et al., 2009; Clarke et al.,
2006; Patargias et al., 2006). The monomeric NMR structure of p7
unveiled a dynamic nature, and the structure identiﬁed predicted
a multifunctional protein rather than one strictly acting as an ion-
channel (Cook et al., 2013). Also, monomeric NMR structural
analysis performed on Flag-p7 from G1b identiﬁed a relevant
allosteric cavity compatible with drug binding. These ﬁndings
highlight the importance of p7 as a potential target for the
development of HCV inhibitors (Foster et al., 2014).
NMR data obtained on oligomerized p7 indicated that the
protein forms a hexameric channel complex in the presence of
detergent, and EM analysis identiﬁed a ﬂower-like shape with six
distinctive petals with the p7 helices oriented toward the lumen of
the ER. The identiﬁed structure also showed an accessible area
facing the interior of the ER that could provide an interaction face
with other viral or host proteins (Luik et al., 2009). Additionally, the
G1b p7 sequence can assemble sequentially to form an oligomer-
ized structure of four to seven subunits with the most putatively
functional oligomer being the hexamer in which the cylindrical
structure accommodates the ﬂower-like shape. The sequential
formation of the channel was suggested to regulate the function
of p7, whereby p7 would be retained in an inactive state that allows
p7 to bind to other viral proteins early in the assembly process.
Subsequently, pore formation could take place to accommodate
channel activity required at a later stage in the life cycle (Chandler
et al., 2012). A more recent NMR structural identiﬁcation of the p7
ion-channel showed that the G5a sequence forms an unusual
hexameric complex with a funnel-like shape see Fig. 3A and B. This
study also suggested that amantadine and rimantadine bind to six
equivalent hydrophobic pockets between the pore-forming and
peripheral helices, deﬁning a possible mechanism of inhibitive
action. OuYang et al., (2013).
The diversity of structural predictions for p7 based on NMR
analyses may be attributed to a number of variables, such as the
different genotypic p7 amino acid sequences, the puriﬁcation
method used, or the solvent and environmental conditions used
in the preparation of the protein for NMR structural analyses.
However, structural agreement in NMR studies will prove to be
important for identiﬁcation of structural features of monomeric
and oligomeric p7 structures, as well as drug binding determi-
nants within p7.
Functional analyses of p7
In 2003 deletion or mutations at the two conserved positively
charged residues in the cytoplasmic loop of p7 within infectious
clones of G1a failed to cause viremia after intrahepatic transfection
in the chimpanzee model. Furthermore, substitution G1a p7 with
p7 from an infectious G2a clone was also not viable. These results
clearly demonstrated the importance of p7 for the virus life cycle
in vivo, as well as the restrictive genotypic context of p7 function
(Sakai et al., 2003). Given the accumulating evidence suggesting
that p7 forms an ion-channel and acts as a viroporin, it is
conceivable that such an activity might be required for the virus
to facilitate entry, assembly or release in a manner similar to that
of other viroporins (Grifﬁn et al., 2003; Pavlovic et al., 2003;
Premkumar et al., 2004).
After the development of the HCVcc system, mutagenesis
studies on various viral proteins for functional analysis became
possible (Lindenbach et al., 2005; Wakita et al., 2005; Zhong et al.,
2005). Early mutational analyses demonstrated the importance of
p7 for virus production (Jones et al., 2007; Steinmann et al., 2007).
Steinmann et al. showed that p7 is involved at a late stage of the
replication cycle, since mutants in p7 reduced both total infectivity
and the ratio of intracellular to released infectious particles.
Successively, p7 was shown to be less likely involved in the viral
entry process due to the maintenance of speciﬁc infectivity
observed in released virions from genomes mutated in p7
(Steinmann et al., 2007). A subsequent study illustrated that p7
mutant genomes generated lower levels of intracellular virus,
released core protein and infectious particles in the culture super-
natant, suggesting involvement of p7 at an early stage of the viral
morphogenesis cycle (Jones et al., 2007). In our lab we have
created an extensive set of triple alanine mutations covering
TM1 and the cytoplasmic loop of p7 (Atoom et al., 2013). These
mutants were subjected to transfection in a single-cycle virus
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production assay that employs a subclone of Huh-7 cells, termed
S29 cells (Russell et al., 2008). These cells express signiﬁcantly
lower levels of CD81 (an HCV entry receptor) and permit RNA
replication and virus production, but do not support entry, thereby
allowing generation of infectious virus without the confounding
effects of multiple infection cycles. Using this assay we illustrated
the importance of each domain in the maintenance of infectious
virus production (Atoom et al., 2013).
Currently, a number of convincing pieces of evidence exist
suggesting that p7 is not involved in the entry steps of the viral life
cycle: (I) HCV pseudoparticles (HCVpp) produced from 293 T cells
lack p7 but remain infectious to hepatocyte-derived cell lines
(Bartosch et al., 2003). (II) cis-expression of p7 during HCVpp
production did not increase infectivity (Flint et al., 2004). (III) HCV
virions are acid-resistant, suggesting that ion-channel activity
during entry is not needed (Tscherne et al., 2006). (IV) p7 from
the related virus BVDV was not found to be a component of the
virion structure (Elbers et al., 1996). (V) We have characterized a
p7 adaptive mutation and found it to increase the levels of
extracellular virus particles even in a virus entry-null system
(Atoom et al., manuscript in preparation). (VI) More importantly,
using an infectious construct containing a double HA-tagged p7, it
was found that p7 was not contained within the virion, even in
concentrated, afﬁnity-puriﬁed or Flag-tagged preparations of virus
(Vieyres et al., 2013). All things considered, a viroporin-like
activity of p7 might be required at a step downstream of virus
entry that resembles the inﬂuenza A M2 activity during viral
egress and HIV-1 Vpu (see Table 1).
Regarding steps subsequent to viral entry, current evidence
indicates that p7 has no role in RNA replication. (I) Replicons
lacking p7 replicate efﬁciently in Huh-7 cells (Lohmann et al.,
1999; Blight et al., 2002) (II) BVDV containing mutations in p7 was
able to replicate in cell culture, but failed to produce infectious
particles (Harada et al., 2000). (III) Mutations or deletions within
p7 generated in the context of HCVcc replicate RNA efﬁciently with
impaired infectious virus production (Jones et al., 2007;
Steinmann et al., 2007).
The establishment of the HCVcc system facilitated many studies
that could not have been performed in the past, and as a result, the
HCV assembly process became intensely investigated. One
intriguing aspect of the assembly mechanism is the accumulation
of core protein around a cellular organelle termed the lipid droplet
(LD), which is proposed to function as a platform for virus
assembly (Miyanari et al., 2007). We have found that efﬁciently-
assembled adaptive strains of JFH-1 as well as genomes mutated in
TM1 and the cytoplasmic loop of p7 show no differences in their
abilities to associate core with LDs (Atoom et al., 2013). However,
others have suggested that core does not accumulate on LD in the
context of an efﬁciently-assembling virus, suggesting that core/LD
accumulation is an indication of an assembly defect (Boson et al.,
2011). It is worth mentioning that an NS2-mutated, assembly-
deﬁcient HCV strain could be rescued by compensatory mutations
in p7 that restored virus production and colocalization of NS2, E2
and NS3 to a site in close proximity to LDs (Jirasko et al., 2010).
Correspondingly, other reports visualized that p7 can manipulate
the intracellular distribution of NS2 and disrupt its binding pattern
with other viral proteins (Ma et al., 2011). This assumption was
conﬁrmed recently by showing that NS2 distribution is affected by
the presence of p7 and its N-terminal signal peptide (Tedbury et
al., 2011). Presenting a different perspective, the efﬁciency of core
accumulation on LDs due to p7 mutations was quantiﬁed and it
was found that mutations in the p7 cytoplasmic loop affected the
unloading of core protein from LDs, resulting in a retention of core
around LDs (Gentzsch et al., 2013). The preceding observations
could indicate that p7 is important for colocalization of NS2 with
LDs, a process that is crucial for NS2 function. Interestingly, p7 has
been also shown important for unloading of newly-formed capsids
toward further assembly, maturation and envelopment (Popescu
et al., 2011; Gentzsch et al., 2013).
Subsequent to core protein recruitment to LDs, core oligo-
merizes to form capsid structures; this presumably facilitates the
formation of multi-order forms during the morphogenesis cycle
that would include monomeric core, partial oligomers, fully
oligomerized capsids and virions associated with triglycerides
and β-lipoproteins, all of which would show different densities
upon intracellular lysate fractionation (Andre et al., 2002;
Gastaminza et al., 2006; Jones et al., 2011). We and others have
shown that p7 mutations in TM1 and the cytoplasmic loop did not
prevent the assembly of core-containing intracellular particles
after iodixanol equilibrium gradient sedimentation (Atoom et al.,
Fig. 3. Monomeric and hexameric structures of p7. (A) Hexameric structure representation of p7 after calculations of 1.5 low-energy structures ensemble using NMR
restraints identiﬁed by the authors. (B) The Fitted model of p7 hexameric structure (the lowest energy structure of the ensemble ﬁtted on the 16 Å EM map with a ﬁtting
correlation equal to 0.94 as calculated by the authors' program chimera). (A) and (B) showing the H1: helix 1 (N terminal helix aa5–16)(blue), H2: middle helical segment, aa
20–41 (yellow) and H3: the third C-terminal helix, aa 48–58 (pink). Reprinted with permission from (OuYang et al., 2013).
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2013; Bentham et al., 2013). Compellingly, another report per-
formed core quantitation on the fractions obtained after sucrose-
based rate zonal fractionation and observed an increased propor-
tion of incompletely assembled capsids. Further analyses on these
fractions indicated that p7 mutations or deletions in the cytoplas-
mic loop led to accumulation of non-enveloped capsids in trans-
fected cells (Gentzsch et al., 2013). These data reﬂect the necessity
of p7 downstream of capsid formation.
The postulation that p7 functions as an ion-channel gained
momentum when it was shown that HCV infection equilibrates
intracellular acidic vesicles. This loss of acidity was not observed
with HCV genomes harboring p7 ion-channel defective mutations
(KR33/35AA in the J4 sequence or RR33/35AA in JFH-1). It was
found that intracellular HCV virions were acid-sensitive, whereas
extracellular virions were acid-stable. In conﬁrmation of this
ﬁnding, the acidiﬁcation inhibitor Baﬁlomycin A1 was able to
rescue virus production of ion-channel defective mutants
(Wozniak et al., 2010). Moreover, we found that triple alanine
substitutions at amino acid residues 33–35 (RGR to AAA) reduced
the amount of E2 present in HCV-transfected cells at 72 h post-
transfection (Atoom et al., 2013). Furthermore, HCV replication-
defective viruses containing mutations in TM1 of p7 or the
cytoplasmic loop showed a restoration of infectivity by in trans
expression of the M2 proton channel of inﬂuenza A, indicative of
an ion-channel requirement for HCV propagation in cell culture
(Bentham et al., 2013). Interestingly, proteinase K digestion of p7
mutant viruses showed signiﬁcant reductions in core protein,
indicative of nucleocapsids lacking envelopes, which demon-
strated that p7 affects virus production at a step prior to envelop-
ment (Gentzsch et al., 2013). p7 ion-channel activity could be an
important step to protect the immature virion from an acidic
environment during the late stage of assembly, particularly at the
envelopment step.
In summation, it is clear that p7 is an important factor in virus
production, speciﬁcally at a late stage in viral assembly, and it
might be that p7 is a dual function protein. In one aspect, p7,
presumably in its monomeric form, assists NS2 in gathering
newly-formed capsids at LDs and glycoprotein complexes on the
ER lumen for proper envelopment. Whereas, in its oligomeric
state, p7 protects glycoproteins from immature degradation dur-
ing trafﬁcking and release through an ion-channel-like activity.
A third possibility, which has received little attention to date, is
that p7 may play some as yet undetermined function that involves
an interaction with a cellular factor. In this regard, p7 has been
suggested to modulate cell death signaling and may be targeted by
cellular kinases (Aweya et al., 2013; Lee et al., 2013). It would be
interesting to know if p7 interacts with cellular proteins in order
to promote virus production.
p7 interactions with other viral proteins
The binding pattern of p7 with other viral proteins is con-
tinually being revealed through genetics-based investigations and
protein–protein interaction analyses. The ﬁrst clue concerning the
necessity for p7 to interact with other proteins came through
intrahepatic RNA injection of chimpanzees with a chimeric virus
generated by replacing the p7 sequence from G1a with that of G2a.
The resulting chimera was not viable after injection, illustrating
p7s genotype-speciﬁc interactions (Sakai et al., 2003). The JFH-1
infectious clone was used in multiple studies to generate infec-
tious chimeras by replacing the core-NS2 (or in some cases core to
part of NS2) fragment of the JFH-1 sequence (G2a) with that of
other genotypes. In this case it was observed that chimeric viruses
were only viable when there was genotypic homology between p7
and substituted structural genes. This characteristic of chimera
construction suggested there is an important interplay between p7
and one or more structural proteins (Pietschmann et al., 2006;
Gottwein et al., 2009; Yi et al., 2007). To successfully create a
viable chimeric construct, H77 (G1a) was fused to JFH-1 (2a) at a
site within NS2 and passaged to allow accumulation of adaptive/
compensatory mutations. The resulting chimera acquired muta-
tions within p7, NS2, E1 and NS3. The combination of p7 and NS2
mutations increased speciﬁc infectivity, suggesting an interaction
between p7 and NS2. This interaction was proposed to anchor p7
to NS2 within the membrane, thereby enhancing the ability of p7
to protect the nascent virion from premature inactivation (Yi et al.,
2007). Furthermore, compensatory mutations in p7 (F776L/S)
signiﬁcantly enhanced the ﬁtness of defective core mutants in
the context of a J6/JFH-1 chimera, providing genetic evidence for
an interaction between p7 and core (Murray et al., 2007). Taken
together, it remains unlikely that a protein the size of p7 interacts
with multiple viral proteins. That being said, it is possible that p7
interacts with a single viral protein in order to stabilize other
downstream interactions and promote viral propagation.
Biochemical and proteomic assays have also been used to
identify p7 binding partners. One report that utilized tagged NS2
showed efﬁcient pull-down with p7, E2, NS3 and to a lower extent,
NS5A (Jirasko et al., 2010). Other work has shown NS2 can be co-
immunoprecipitated with E1 as well (Ma et al., 2011). Importantly,
mutagenesis studies have demonstrated that p7 affects NS2
colocalization with E2 and NS3 around LDs, and p7 basic loop
mutations signiﬁcantly reduced NS2 interactions with E1, E2 and
NS3 (Jirasko et al., 2010; Ma et al., 2011). It is noteworthy that
mutations in the two basic residues of the cytoplasmic loop of p7
caused considerable alteration of intracellular distribution of NS2
and E2 (Ma et al., 2011). However, it is difﬁcult to conclude
whether these results indicate a direct interaction with the loop,
or if the removal of the charged residues changes the topology of
p7 to indirectly affect the localization of other proteins. Recently,
NS2 was conﬁrmed to interact with p7 and E2; mutations in p7
changed subcellular localization of NS2 and reduced viral assem-
bly (Popescu et al., 2011). p7 interaction with NS2 was shown to
be independent of p7 ion-channel activity and NS2 localization
was affected primarily by p7 and its signal peptide at the
N-terminus, suggesting an alternative function of p7 during the
assembly process (Tedbury et al., 2011). More recently, a co-
immunoprecipitation study using a replication-competent virus
containing a double HA-tagged p7 conﬁrmed the speciﬁc interac-
tion between p7 and NS2, which was proposed to be critical for
virus production in cell culture (Vieyres et al., 2013). Despite the
discrepancies observed for NS2 as a p7 binding partner we can
conclude that NS2 maintains the organization of the viral assem-
bly process and that p7 is a mandatory interaction partner. It is
also plausible that p7 binds NS2 in a manner that regulates its
function in virus assembly.
The size and topology of p7 have made it poorly immunogenic for
antibody production. Consequently, the determination of p7 binding
partners by standard methods is problematic and difﬁcult to inter-
pret. The topology of p7 in membrane structures and data generated
from puriﬁed or tagged proteins might not reﬂect the actual picture.
Considering p7 exists as multiple forms: unprocessed E2-p7, p7-NS2,
monomeric p7 or oligomers, reproducibility of data becomes further
complicated. Accordingly, more accurate experimental approaches
need to be investigated or identiﬁed to better deﬁne the protein–
protein interaction activities of p7, both viral and potentially cellular.
Conclusion
p7 is required for in vivo infectivity, and important for
infectious virus production in cell culture. For unknown reasons,
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the cleavage of p7 from adjacent viral proteins is delayed, leading
to the presence of precursor polypeptides (E2-p7, p7-NS2 or E2-
p7-NS2) proposed to have regulatory roles in virus production.
Recent structural and topological studies have conﬁrmed that p7
mainly localizes to the ER and contains two trans-membrane
domains connected by a short cytoplasmic loop. By oligomerizing
in the membrane p7 is believed to form an ion-channel that
facilitates proton permeabilization in order to equilibrate intracel-
lular vesicle pH to promote infectious virus production. The ion-
channel activity can be inhibited by several compounds with
BIT225 and iminosugar derivatives showing the most promising
results. Moreover, p7 interacts with NS2 and supports a late step in
viral assembly and envelopment. The interaction pattern of p7
with other viral and host factors, and its exact contribution to
infectious virus production remains ambiguous. In our opinion,
the contrasting hypotheses in the ﬁeld regarding the function of
p7 partly stem from the fact that numerous systems are being
employed to analyze this protein (artiﬁcial membranes, single
protein expression, HCVcc and HCVcc with tagged p7). Although
all of these relevant systems provide critical information regarding
p7, it can be difﬁcult to reconcile the various results. Perhaps the
greatest limitation we face at present is the lack of a reliable
monoclonal antibody recognizing p7, and the generation of such
would be a major advance that would allow relevant analysis of
unmodiﬁed p7 in the context of the full viral genome.
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